Download Full eBooks in PDF
Medicare Prescription Drug Improvement And Modernization Act Of 2003 Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Medicare Prescription Drug Improvement And Modernization Act Of 2003 book. This book definitely worth reading, it is an incredibly well-written.
Author : CCH Incorporated
Publisher : Wolters Kluwer
Page : 642 pages
File Size : 47,9 Mb
Release : 2004-01-01
Category : Business & Economics
ISBN : 0808011294
Author : United States. Congress
Publisher : Unknown
Page : 850 pages
File Size : 49,6 Mb
Release : 2003
Category : Electronic government information
ISBN : PURD:32754077083461
Author : CCH Incorporated
Publisher : Unknown
Page : 681 pages
File Size : 51,8 Mb
Release : 2003
Category : Medicare
ISBN : OCLC:53997213
Author : United States. Congress
Publisher : Unknown
Page : 850 pages
File Size : 51,6 Mb
Release : 2003
Category : Medical care, Cost of
ISBN : 0160679761
Author : Carla D. Jones
Publisher : Unknown
Page : 131 pages
File Size : 44,8 Mb
Release : 2004-09
Category : Electronic
ISBN : 1423519469
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 added an outpatient prescription drug benefit to Medicare. This benefit had been a recurring topic among lawmakers, attempted many times since Medicare was enacted in 1965. The 2003 legislation marked the most significant and expensive overhaul of Medicare since its creation. It occurred at a time of record federal budget deficits and Republican control of Congress and the White House. The major compromise that allowed this legislation to succeed concerned the total funding to be made available, the amount of privatization in the design and administration of the benefit, and the scope of the coverage. This thesis identifies and describes the primary stakeholders involved and their influences on the benefit, including political parties, Congress, the Bush Administration and interest groups, and summarizes previous attempts at similar legislation. Sources include congressional testimony, government cost estimates, legislation, journal articles, and think-tanks. The thesis analyzes the legislative process that produced the Medicare reform and identifies problems and issues resulting from it.
Author : United States. Congress. House
Publisher : Unknown
Page : 0 pages
File Size : 44,8 Mb
Release : 2007
Category : Drugs
ISBN : OCLC:785155240
Author : United States. Congress. House. Committee on Rules
Publisher : Unknown
Page : 2 pages
File Size : 40,8 Mb
Release : 2003
Category : Medicare
ISBN : PURD:32754077090219
Author : United States. Congress. House. Committee on Energy and Commerce
Publisher : Unknown
Page : 256 pages
File Size : 54,7 Mb
Release : 2003
Category : Medicare
ISBN : STANFORD:36105050314579
Author : United States. Congress. House. Committee on Rules
Publisher : Unknown
Page : 136 pages
File Size : 51,6 Mb
Release : 2003
Category : Bills, Legislative
ISBN : LOC:00114385566
Author : Anna Cook,Andrew Stocking
Publisher : Unknown
Page : 48 pages
File Size : 46,7 Mb
Release : 2014-09-03
Category : Electronic
ISBN : 1457856638
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In FY 2013, Medicare Part D covered 39 million people. The federal government spent $59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was $50 billion, which represented 10% of net federal spending for Medicare. A combination of broader trends in the prescription drug market and lower-than-expected enrollment in Part D has contributed to much lower spending for the program than projected when the MMA became law in 2003. This report examines the federal budgetary cost and competitive design of Medicare Part D and compares Medicare Part D and Medicaid Fee for Service. Figures and tables. This is a print on demand report.
Author : Anonim
Publisher : Unknown
Page : 126 pages
File Size : 48,8 Mb
Release : 2003
Category : Electronic
ISBN : UOM:39015090407233
Author : Jennifer O'Sullivan
Publisher : Novinka Books
Page : 0 pages
File Size : 44,8 Mb
Release : 2008
Category : Insurance, Pharmaceutical services
ISBN : 1604566221
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 established a new voluntary prescription drug benefit under a new Medicare Part D, effective January 1, 2006. Prescription drug coverage is provided through private prescription drug plans (PDPs) or Medicare Advantage prescription drug (MA-PD) plans. Beneficiaries must enrol in one of these private plans in order to obtain their drug benefits. The program relies on these private plans to provide coverage and to bear some of the financial risk for drug costs; federal subsidies covering the bulk of the risk are provided to encourage participation. At a minimum, plans offer "standard coverage" or alternative coverage with actuarially equivalent benefits. They may also offer enhanced benefits. All plans are required to meet certain minimum requirements, including those related to beneficiary protections. However, there are significant differences among plans in terms of benefit design, drugs included on plan formularies (i.e., list of covered drugs), cost-sharing applicable for particular drugs, and monthly premiums. In general, beneficiaries can enrol in a plan, or change plan enrolment, when they first become eligible for Medicare or during the annual open enrolment period. The open enrolment period for 2008 is from November 15, 2007, to December 31, 2007. Plans can change from year to year. Beneficiary needs may also change. Therefore, beneficiaries should review their plan choice annually to make sure that their chosen plan continues to meet their needs.
Author : Institute of Medicine,Board on Health Sciences Policy,Committee on Accelerating Rare Diseases Research and Orphan Product Development
Publisher : National Academies Press
Page : 442 pages
File Size : 45,5 Mb
Release : 2011-04-03
Category : Medical
ISBN : 9780309158060
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Author : United States. Congress. House. Committee on Standards of Official Conduct
Publisher : Unknown
Page : 122 pages
File Size : 43,6 Mb
Release : 2004
Category : Government publications
ISBN : MINN:31951D025700486
Author : United States Government Accountability Office
Publisher : Createspace Independent Publishing Platform
Page : 36 pages
File Size : 47,8 Mb
Release : 2017-09-15
Category : Electronic
ISBN : 1976433673
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established a voluntary outpatient prescription drug benefit, known as Medicare Part D. Private sponsors have contracted with the Centers for Medicare & Medicaid Services (CMS) to provide this benefit and are offering over 1,400 stand-alone prescription drug plans (PDP). Depending on where they live, beneficiaries typically have a choice of 40 to 50 PDPs, which vary in cost and coverage. MMA required each PDP sponsor to staff a toll-free call center, which serves as a key source of the information that beneficiaries need to make informed choices among PDPs. GAO examined (1) whether PDP sponsors provide prompt, courteous, and helpful service to Medicare beneficiaries and others and (2) the extent to which PDP sponsor call centers provide accurate and complete information to Medicare beneficiaries and other callers. To address these objectives, we made 900 calls to 10 of the largest PDP sponsor call centers during March 2006, posing one of five questions about their Part D plans during each call. We tracked the amount of time it took to reach a